REG - Ondine Biomedical - Economic study suggests c.£200 million UK savings

Ondine BiomedicalAnnouncement

09/04/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250409:nRSI2140Ea&default-theme=true

RNS Number : 2140E  Ondine Biomedical Inc.  09 April 2025

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine", or the "Company")

YHEC Health Economic study suggests Steriwave technology could save UK
hospitals c.£200 million savings (£2.38 saved for every £1 spent) from
reducing surgical site infections in major surgeries

Ondine Biomedical Inc. (LON: OBI) announces that a new health economic
analysis by the York Health Economics Consortium (YHEC) has confirmed that
using Steriwave(®) nasal decolonization prior to major surgery delivers
substantial net cost savings. YHEC has demonstrated that for every £1 spent
on Steriwave to prevent surgical site infections (SSI), the NHS can save an
average of £1.49 to £2.38 across major surgical specialties. With £38 to
£107 net saving per operation, Steriwave has the potential to save the UK
hospitals, including the NHS, up to £200 million annually. 1 

The YHEC analysis, which employed rigorous micro-costing and literature-based
methodologies, highlights Steriwave's compelling health economic advantages
across various surgical categories:

·      Overall Surgeries (hip, knee, spinal, cardiac, vascular): the
micro-costing analysis showed that Steriwave achieved net cost savings of
£38,180 per 1,000 patients, representing a return of £1.49 saved for every
£1 spent. A broader literature-based costing method further validated these
benefits, yielding aggregate net savings of £107,530 per 1,000 patients, or
£2.38 saved for every £1 spent.

·      Cardiac Surgeries: Steriwave demonstrated the most significant
savings in cardiac surgeries, with net cost savings reaching up to £228,090
per 1,000 patients. This translates to a return of up to £3.92 for every £1
spent.

·      Hip and Knee Surgeries: For both hip and knee procedures,
Steriwave generated substantial net savings of approximately £86,650 and
£84,430 per 1,000 patients, respectively, equating to approximately £2.10 in
savings for every £1 spent.

Carolyn Cross, CEO of Ondine Biomedical, stated:

"In an era where healthcare systems face unprecedented challenges with
resource constraints, lengthy waitlists, and budgetary pressures, infection
prevention is paramount for both cost containment and patient well-being.
While the substantial return on investment demonstrated by this analysis is
crucial for driving the widespread adoption of this innovative, non-antibiotic
presurgical prevention protocol, it is imperative that we acknowledge the
profound impact SSI have on patients and their families.

"The agonizing reality of a prolonged recovery and extended hospital stays
following a seemingly routine surgery like a knee replacement can be
life-altering. Ondine Biomedical is dedicated to empowering healthcare systems
to proactively prevent these devastating infections. We are incredibly proud
that Steriwave offers the potential for significant hospital savings while
simultaneously improving patient outcomes."

The YHEC findings align with previously reported clinical effectiveness data
from Mid Yorkshire Teaching NHS Trust, the first NHS Trust to implement
Steriwave. Real-world data showed that Steriwave prevents 9.8 SSIs (0.98%) per
1,000 patients more effectively than the standard of care alone, contributing
to a significant reduction of 139 hospital bed days.

Dr. Stuart Bond, Consultant Antimicrobial Pharmacist and Director of
Innovation at Mid Yorkshire Teaching NHS Trust, stated:

"The YHEC analysis provides valuable confirmation of the link between
Steriwave and reduced SSI rates in orthopaedic surgery, even when used
alongside existing protocols. We are keen to explore Steriwave's potential as
a replacement for current standards and its application in surgical
specialties with higher SSI rates. The positive feedback from patients and
staff highlights its seamless integration and high level of acceptance."

The YHEC economic analysis was commissioned by Health Innovation Network
Yorkshire and Humber and Ondine Biomedical to gain a deeper understanding of
Steriwave's health economic impact in the UK. Full details of the analysis are
being prepared for publication.

Steriwave is a non-invasive nasal decolonization treatment that utilizes a
proprietary light-activated antimicrobial agent to eliminate harmful pathogens
in the nose within five minutes. Steriwave is distributed in the UK by
Mölnlycke Health Care, a global leader in MedTech, renowned for its
innovative solutions in wound care and surgical procedures.

Enquiries:

 Ondine Biomedical Inc.                                     www.ondinebio.com
 Carolyn Cross, CEO                                         Via Vane Percy & Roberts
 Strand Hanson Limited (Nominated & Financial Adviser)
 James Harris, Richard Johnson                              +44 (0)20 7409 3494
 RBC Capital Markets (Broker)
 Rupert Walford, Kathryn Deegan                             +44 (0)20 7653 4000
 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy, Amanda Bernard                           +44 (0)77 1000 5910

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies (also known as 'photodisinfection').
Ondine has a pipeline of investigational products, based on its proprietary
photodisinfection technology, in various stages of development.

Ondine's nasal photodisinfection system has a CE mark in Europe and is
approved in Canada and several other countries under the name Steriwave(®).
In the US, it has been granted Qualified Infectious Disease Product
designation and Fast Track status by the FDA and is currently undergoing
clinical trials for regulatory approval. Products beyond nasal
photodisinfection include therapies for a variety of medical indications such
as chronic sinusitis, ventilator-associated pneumonia, burns and other
indications.

About Mid Yorkshire Teaching NHS Trust

The UK's Mid Yorkshire Teaching NHS Trust provides acute, community and
specialist health care services to around half a million people living in
Wakefield and North Kirklees. It has three hospitals at Dewsbury, Pontefract
and Wakefield (Pinderfields), and also provide care in community settings such
as GP surgeries, health centres and clinics as well as in people's own homes.

About York Health Economics Consortium (YHEC):

York Health Economics Consortium (YHEC) is a health economic consulting
company formed in 1986 and wholly owned by the University of York. YHEC is the
University of York's main consultancy provider of health economics expertise.

About Mölnlycke Health Care

Mölnlycke Health Care is a world-leading MedTech company that specializes in
innovative solutions for wound care and surgical procedures. Mölnlycke
products and solutions are used daily by hospitals, health care providers and
patients in over 100 countries around the world. Founded in 1849, Mölnlycke
is owned by Investor AB and headquartered in Sweden. www.molnlycke.com
(https://www.molnlycke.com/)

 

 1  Surgical volume data from privately-commissioned market research.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDBGDSDSGDGUI